Showing 47 results
-
Media Release /For over two decades, NOYCIA has fueled emerging research in Canada, driving scientific knowledge in cancerMontreal, QC – June 10, 2025 – Novartis Canada is pleased to announce the winners…
-
Media Release /• Applications are now being accepted, with $500,000 in grants to be awarded to projects focused on improving health equity in CanadaMontreal, Quebec, May 14, 2025 – Novartis…
-
Media Release /Fabhalta® is the first oral monotherapy for previously treated and treatment-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH)1,2 Significant unmet need remains in PNH, a chronic, rare…
-
Media Release /Ontario is the first province in Canada to offer public reimbursement for Pluvicto™, a targeted radioligand therapy for patients with progressive PSMA-positive metastatic castration-resistant…
-
Media Release /Targeted radioligand therapy closer to public reimbursement for eligible Canadian patients with PSMA-positive metastatic castration-resistant prostate cancerMontreal, Quebec, December 13, 2024 –…
-
Media Release /The Novartis Health Equity Initiative was launched earlier this year as a call for ideas to help tackle persistent health disparities and promote equal access to healthcare in CanadaSubmissions were…
-
Media Release /Montreal, November 15, 2024 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is extremely disappointed that negotiations for PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection), a…
-
Media Release /Prioritization of screening programs for spinal muscular atrophy (SMA) will ensure early diagnosis across Canada and bring lasting impact to babies and caregivers Montreal, August 20, 2024 —…
-
Media Release /Montréal, QC, July 8, 2024 – Novartis Pharmaceuticals Canada Inc. (Novartis) today announced the launch of a new health equity initiative, aimed at addressing health disparities and promoting…
-
Media Release /NOYCIA recognizes excellence in Canadian oncology research as part of Novartis Canada’s commitment to reimagining medicineMontreal, QC, June 11, 2024 – Novartis Canada is pleased to announce the…
